<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01544920</url>
  </required_header>
  <id_info>
    <org_study_id>P07755</org_study_id>
    <secondary_id>2011-001345-32</secondary_id>
    <secondary_id>MK-3034-040</secondary_id>
    <secondary_id>CTRI/2012/12/003200</secondary_id>
    <secondary_id>PHRR131022-000133</secondary_id>
    <nct_id>NCT01544920</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)</brief_title>
  <official_title>A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to compare the efficacy of two boceprevir
      (BOC)-containing therapeutic regimens in the treatment of naïve participants with chronic
      hepatitis C virus (HCV) genotype 1 who have the IL28B CC allele.

      The regimens differ in the treatment for participants who achieve undetectable HCV
      ribonucleic acid (RNA) at the end of the peginterferon alfa-2a (peg-IFN) plus ribavirin (RBV)
      4 week lead-in. Participants receive either peg-IFN + RBV (Arm 1) or BOC + peg-IFN + RBV (Arm
      2). The hypothesis is that Arm 2 is noninferior to Arm 1 in the proportion of participants
      with undetectable HCV RNA at Follow-Up (FU) Week 24.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) 24 Weeks After Completing Study Treatment (SVR24)</measure>
    <time_frame>Up to Week 74</time_frame>
    <description>SVR24 rates were determined for all participants in Arm 1 and Arm 2. HCV RNA viral load was determined using the Roche COBAS® AmpliPrep/COBAS® TaqMan HCV Test v1.0, which has a lower limit of quantification of 43 IU/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Had Undetectable HCV RNA at Week 4 Achieving SVR24</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>SVR24 rates were determined for only participants that had undetectable HCV RNA at Week 4 of treatment (Arm 1a and Arm 2a). HCV RNA viral load was determined using the Roche COBAS® AmpliPrep/COBAS® TaqMan HCV Test v1.0, which has a lower limit of quantification of 43 IU/mL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">737</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Arm 1: peg-IFN + RBV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received an initial 4 week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, participants with undetectable HCV RNA received open label peg-IFN + RBV for an additional 18 weeks (total of 24 weeks of peg-IFN/RBV therapy) [Arm 1a]. Participants with detectable HCV RNA at Week 4 had BOC added to the peg-IFN + RBV regimen at Week 6 and then followed the Response Guided Therapy (RGT) regimen for BOC + peg-IFN + RBV [Arm 1b].</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: BOC + peg-IFN + RBV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received an initial 4-week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, all participants had BOC added to the peg-IFN + RBV regimen at Week 6 regardless of HCV RNA levels. Participants who had undetectable HCV RNA at Week 4 continued on the BOC + peg-IFN + RBV regimen for an additional 20 weeks (total of 24 weeks of BOC + peg-IFN + RBV therapy) [Arm 2a]. Participants with detectable HCV RNA at Week 4 followed the RGT regimen for BOC + peg-IFN + RBV [Arm 2b].</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>peg-Interferon alfa-2a</intervention_name>
    <description>peg-IFN (180 ug) was taken once weekly via subcutaneous injection.</description>
    <arm_group_label>Arm 1: peg-IFN + RBV</arm_group_label>
    <arm_group_label>Arm 2: BOC + peg-IFN + RBV</arm_group_label>
    <other_name>Pegasys™; SCH 054031</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>RBV 200 mg tablets taken by mouth at a total daily dose of 1,000 mg (body weight &lt;75 kilograms [kg]) or 1,200 mg (body weight ≥75 kg) with total daily dose divided into 2 dosings.</description>
    <arm_group_label>Arm 1: peg-IFN + RBV</arm_group_label>
    <arm_group_label>Arm 2: BOC + peg-IFN + RBV</arm_group_label>
    <other_name>Rebetol™; 018908</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Boceprevir</intervention_name>
    <description>Four 200 mg BOC capsules taken three times a day by mouth for a total daily dose of 2,400 mg.</description>
    <arm_group_label>Arm 1: peg-IFN + RBV</arm_group_label>
    <arm_group_label>Arm 2: BOC + peg-IFN + RBV</arm_group_label>
    <other_name>SCH 503034; Victrelis™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is ≥ 40 kg and ≤ 125 kg.

          -  Documented CHC genotype 1 with HCV RNA ≥10,000 International Units (IU)/mL

          -  Has IL-28B CC allele gene

          -  Has had a liver biopsy without evidence of cirrhosis and hepatocellular carcinoma
             (non-invasive fibroscan and Fibrotest can also be used for staging of liver disease).

        Exclusion Criteria:

          -  Co-infection with the human immunodeficiency virus (HIV) or hepatitis B virus
             (Hepatitis B surface antigen [HBsAg] or HIV positive).

          -  Previously treated with an interferon and ribavirin regimen or HCV direct acting
             antiviral regimen.

          -  Treatment for hepatitis C with any investigational medication, or prior treatments
             with herbal remedies with known hepatotoxicity

          -  Receiving any medication(s) within 2 weeks prior to the Day 1 visit that are highly
             dependent on Cytochrome P450 3A4 (CYP3A4/5) for clearance, and for which elevated
             plasma concentrations could be associated with serious and/or life-threatening events

          -  Participation in any other clinical trial within 30 days of the screening visit in
             this trial or intention to participate in another clinical trial during participation
             in this trial.

          -  Evidence of decompensated liver disease or hepatocellular carcinoma (HCC)

          -  Is diabetic and/or hypertensive with significant retinopathy

          -  Has any known medical condition that could interfere with the participation in and
             completion of the trial including immunologically-mediated disease, chronic pulmonary
             disease, or current or history of any clinically significant cardiac
             abnormalities/dysfunction.

          -  Evidence of active or suspected malignancy, or a history of malignancy, within the
             last 5 years

          -  Hemoglobin &lt;12 g/dL for females and &lt;13 g/dL for males

          -  Neutrophils &lt;1,500/mm^3, or &lt;1,200/mm^3 for participants of African descent

          -  Platelets &lt;150,000/mm^3

          -  Direct bilirubin &gt;1.5 x upper limit of normal (ULN) of the laboratory reference range.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hong Kong</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2012</study_first_submitted>
  <study_first_submitted_qc>March 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2012</study_first_posted>
  <results_first_submitted>April 22, 2016</results_first_submitted>
  <results_first_submitted_qc>April 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 30, 2016</results_first_posted>
  <last_update_submitted>March 10, 2017</last_update_submitted>
  <last_update_submitted_qc>March 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: Peg-IFN + RBV</title>
          <description>Participants received an initial 4 week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, participants with undetectable HCV RNA received open label peg-IFN + RBV for an additional 18 weeks (total of 24 weeks of peg-IFN/RBV therapy) [Arm 1a]. Participants with detectable HCV RNA at Week 4 had BOC added to the peg-IFN + RBV regimen at Week 6 and then followed the Response Guided Therapy (RGT) regimen for BOC + peg-IFN + RBV [Arm 1b].</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: BOC + Peg-IFN + RBV</title>
          <description>Participants received an initial 4-week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, all participants had BOC added to the peg-IFN + RBV regimen at Week 6 regardless of HCV RNA levels. Participants who had undetectable HCV RNA at Week 4 continued on the BOC + peg-IFN + RBV regimen for an additional 20 weeks (total of 24 weeks of BOC + peg-IFN + RBV therapy) [Arm 2a]. Participants with detectable HCV RNA at Week 4 followed the RGT regimen for BOC + peg-IFN + RBV [Arm 2b].</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="368"/>
                <participants group_id="P2" count="369"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="349"/>
                <participants group_id="P2" count="346"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: Peg-IFN + RBV</title>
          <description>Participants received an initial 4 week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, participants with undetectable HCV RNA received open label peg-IFN + RBV for an additional 18 weeks (total of 24 weeks of peg-IFN/RBV therapy) [Arm 1a]. Participants with detectable HCV RNA at Week 4 had BOC added to the peg-IFN + RBV regimen at Week 6 and then followed the Response Guided Therapy (RGT) regimen for BOC + peg-IFN + RBV [Arm 1b].</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: BOC + Peg-IFN + RBV</title>
          <description>Participants received an initial 4-week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, all participants had BOC added to the peg-IFN + RBV regimen at Week 6 regardless of HCV RNA levels. Participants who had undetectable HCV RNA at Week 4 continued on the BOC + peg-IFN + RBV regimen for an additional 20 weeks (total of 24 weeks of BOC + peg-IFN + RBV therapy) [Arm 2a]. Participants with detectable HCV RNA at Week 4 followed the RGT regimen for BOC + peg-IFN + RBV [Arm 2b].</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="368"/>
            <count group_id="B2" value="369"/>
            <count group_id="B3" value="737"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.9" spread="12.0"/>
                    <measurement group_id="B2" value="42.4" spread="12.4"/>
                    <measurement group_id="B3" value="43.1" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="315"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="221"/>
                    <measurement group_id="B3" value="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) 24 Weeks After Completing Study Treatment (SVR24)</title>
        <description>SVR24 rates were determined for all participants in Arm 1 and Arm 2. HCV RNA viral load was determined using the Roche COBAS® AmpliPrep/COBAS® TaqMan HCV Test v1.0, which has a lower limit of quantification of 43 IU/mL.</description>
        <time_frame>Up to Week 74</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all participants who completed the 4-week peg-IFN + RBV lead-in and who were randomized at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Peg-IFN + RBV</title>
            <description>Participants received an initial 4 week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, participants with undetectable HCV RNA received open label peg-IFN + RBV for an additional 18 weeks (total of 24 weeks of peg-IFN/RBV therapy) [Arm 1a]. Participants with detectable HCV RNA at Week 4 had BOC added to the peg-IFN + RBV regimen at Week 6 and then followed the Response Guided Therapy (RGT) regimen for BOC + peg-IFN + RBV [Arm 1b].</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: BOC + Peg-IFN + RBV</title>
            <description>Participants received an initial 4-week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, all participants had BOC added to the peg-IFN + RBV regimen at Week 6 regardless of HCV RNA levels. Participants who had undetectable HCV RNA at Week 4 continued on the BOC + peg-IFN + RBV regimen for an additional 20 weeks (total of 24 weeks of BOC + peg-IFN + RBV therapy) [Arm 2a]. Participants with detectable HCV RNA at Week 4 followed the RGT regimen for BOC + peg-IFN + RBV [Arm 2b].</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) 24 Weeks After Completing Study Treatment (SVR24)</title>
          <description>SVR24 rates were determined for all participants in Arm 1 and Arm 2. HCV RNA viral load was determined using the Roche COBAS® AmpliPrep/COBAS® TaqMan HCV Test v1.0, which has a lower limit of quantification of 43 IU/mL.</description>
          <population>The Full Analysis Set (FAS) consisted of all participants who completed the 4-week peg-IFN + RBV lead-in and who were randomized at Week 4.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="369"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7"/>
                    <measurement group_id="O2" value="88.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in percentage of participants achieving SVR24</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was declared if the lower bound of the 95% CI of the difference in SVR24 % exceeded -10%.</non_inferiority_desc>
            <param_type>Difference in SVR24% in Arm 2 vs. Arm 1</param_type>
            <param_value>1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>6.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Had Undetectable HCV RNA at Week 4 Achieving SVR24</title>
        <description>SVR24 rates were determined for only participants that had undetectable HCV RNA at Week 4 of treatment (Arm 1a and Arm 2a). HCV RNA viral load was determined using the Roche COBAS® AmpliPrep/COBAS® TaqMan HCV Test v1.0, which has a lower limit of quantification of 43 IU/mL.</description>
        <time_frame>Up to Week 48</time_frame>
        <population>The Full Analysis Set (FAS) consisted of all participants who completed the 4-week peg-IFN + RBV lead-in, who were randomized at Week 4, and also had undetectable HCV RNA at Week 4.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1a: Peg-IFN + RBV 24 Weeks</title>
            <description>Participants received an initial 4 week lead-in of peg-IFN + RBV. The subset of participants with undetectable HCV RNA at Week 4 received an additional 20 weeks of peg-IFN + RBV for a total of 24 weeks of peg-IFN + RBV therapy.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2a: BOC + Peg-IFN + RBV 24 Weeks</title>
            <description>Participants received an initial 4 week lead-in of peg-IFN + RBV. The subset of participants with undetectable HCV RNA at Week 4 received an additional 20 weeks of BOC + peg-IFN + RBV for a total of 24 weeks of BOC (added at Week 4) + peg-IFN + RBV therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Had Undetectable HCV RNA at Week 4 Achieving SVR24</title>
          <description>SVR24 rates were determined for only participants that had undetectable HCV RNA at Week 4 of treatment (Arm 1a and Arm 2a). HCV RNA viral load was determined using the Roche COBAS® AmpliPrep/COBAS® TaqMan HCV Test v1.0, which has a lower limit of quantification of 43 IU/mL.</description>
          <population>The Full Analysis Set (FAS) consisted of all participants who completed the 4-week peg-IFN + RBV lead-in, who were randomized at Week 4, and also had undetectable HCV RNA at Week 4.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.0"/>
                    <measurement group_id="O2" value="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The observed lower bound of the 95% CI for the difference was 2.5% (which exceeds 0) for BOC added to peg-IFN + RBV in contrast to peg-IFN + RBV alone.</non_inferiority_desc>
            <param_type>Difference in SVR24%</param_type>
            <param_value>10.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.5</ci_lower_limit>
            <ci_upper_limit>18.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 78 weeks</time_frame>
      <desc>An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. The All Participants as Treated (APaT) population includes all participants who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: Peg-IFN + RBV</title>
          <description>Participants received an initial 4 week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, participants with undetectable HCV RNA received open label peg-IFN + RBV for an additional 18 weeks (total of 24 weeks of peg-IFN/RBV therapy) [Arm 1a]. Participants with detectable HCV RNA at Week 4 had BOC added to the peg-IFN + RBV regimen at Week 6 and then followed the Response Guided Therapy (RGT) regimen for BOC + peg-IFN + RBV [Arm 1b].</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: BOC + Peg-IFN + RBV</title>
          <description>Participants received an initial 4-week lead-in of peg-IFN + RBV. Following HCV RNA analysis at Week 4, all participants had BOC added to the peg-IFN + RBV regimen at Week 6 regardless of HCV RNA levels. Participants who had undetectable HCV RNA at Week 4 continued on the BOC + peg-IFN + RBV regimen for an additional 20 weeks (total of 24 weeks of BOC + peg-IFN + RBV therapy) [Arm 2a]. Participants with detectable HCV RNA at Week 4 followed the RGT regimen for BOC + peg-IFN + RBV [Arm 2b].</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Inflammatory bowel disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Herpes pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="368"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Prothrombin time prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Conjunctival melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Miscarriage of partner</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="368"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="368"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="348" subjects_at_risk="368"/>
                <counts group_id="E2" subjects_affected="351" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="219" subjects_affected="169" subjects_at_risk="368"/>
                <counts group_id="E2" events="210" subjects_affected="168" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="66" subjects_affected="39" subjects_at_risk="368"/>
                <counts group_id="E2" events="46" subjects_affected="33" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="194" subjects_affected="109" subjects_at_risk="368"/>
                <counts group_id="E2" events="161" subjects_affected="108" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="19" subjects_at_risk="368"/>
                <counts group_id="E2" events="28" subjects_affected="24" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="368"/>
                <counts group_id="E2" events="26" subjects_affected="22" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="26" subjects_affected="22" subjects_at_risk="368"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="77" subjects_affected="62" subjects_at_risk="368"/>
                <counts group_id="E2" events="55" subjects_affected="49" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="26" subjects_affected="25" subjects_at_risk="368"/>
                <counts group_id="E2" events="28" subjects_affected="26" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="368"/>
                <counts group_id="E2" events="39" subjects_affected="35" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="117" subjects_affected="100" subjects_at_risk="368"/>
                <counts group_id="E2" events="112" subjects_affected="94" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="68" subjects_affected="46" subjects_at_risk="368"/>
                <counts group_id="E2" events="78" subjects_affected="53" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="108" subjects_affected="82" subjects_at_risk="368"/>
                <counts group_id="E2" events="90" subjects_affected="74" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="39" subjects_affected="36" subjects_at_risk="368"/>
                <counts group_id="E2" events="32" subjects_affected="26" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="135" subjects_affected="118" subjects_at_risk="368"/>
                <counts group_id="E2" events="154" subjects_affected="117" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="39" subjects_affected="34" subjects_at_risk="368"/>
                <counts group_id="E2" events="48" subjects_affected="35" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="148" subjects_affected="101" subjects_at_risk="368"/>
                <counts group_id="E2" events="243" subjects_affected="148" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="29" subjects_affected="24" subjects_at_risk="368"/>
                <counts group_id="E2" events="33" subjects_affected="31" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="30" subjects_affected="24" subjects_at_risk="368"/>
                <counts group_id="E2" events="41" subjects_affected="29" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="60" subjects_affected="54" subjects_at_risk="368"/>
                <counts group_id="E2" events="55" subjects_affected="53" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="49" subjects_affected="44" subjects_at_risk="368"/>
                <counts group_id="E2" events="52" subjects_affected="45" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="79" subjects_affected="61" subjects_at_risk="368"/>
                <counts group_id="E2" events="74" subjects_affected="58" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="51" subjects_affected="46" subjects_at_risk="368"/>
                <counts group_id="E2" events="48" subjects_affected="42" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="69" subjects_affected="65" subjects_at_risk="368"/>
                <counts group_id="E2" events="95" subjects_affected="94" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="152" subjects_affected="118" subjects_at_risk="368"/>
                <counts group_id="E2" events="148" subjects_affected="100" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="29" subjects_affected="26" subjects_at_risk="368"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="38" subjects_affected="29" subjects_at_risk="368"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="73" subjects_affected="70" subjects_at_risk="368"/>
                <counts group_id="E2" events="57" subjects_affected="53" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="43" subjects_affected="38" subjects_at_risk="368"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="83" subjects_affected="66" subjects_at_risk="368"/>
                <counts group_id="E2" events="56" subjects_affected="52" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="36" subjects_affected="34" subjects_at_risk="368"/>
                <counts group_id="E2" events="38" subjects_affected="34" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="368"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="76" subjects_affected="72" subjects_at_risk="368"/>
                <counts group_id="E2" events="74" subjects_affected="70" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="45" subjects_affected="44" subjects_at_risk="368"/>
                <counts group_id="E2" events="41" subjects_affected="41" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="85" subjects_affected="75" subjects_at_risk="368"/>
                <counts group_id="E2" events="84" subjects_affected="77" subjects_at_risk="369"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="82" subjects_affected="69" subjects_at_risk="368"/>
                <counts group_id="E2" events="85" subjects_affected="67" subjects_at_risk="369"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator agrees not to publish or publicly present any interim results of the trial without the prior written consent of the sponsor. The investigator further agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

